Biomarin Pharmaceutical Inc

BMRN · Moat type: REGULIERUNG

MoatScore

3/10

Fair Value

31 USD

Margin of Safety

-90.2 %

Rating

BEOBACHTEN

GESCHÄFTSMODELL BioMarin Pharmaceutical develops and markets medicines for rare genetic disorders, whose revenue is substantially driven by patent-protected pricing and regulatory orphan drug designations. TECHNISCH FUNDAMENTAL MOAT-CHECK MOAT BURGGRABEN KRISENRESISTENZ KRISE BEWERTUNG RISIKEN AUSBLICK FAZIT Buffett-Bewertung:

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.